Physician profile
Mark E Garcia
NPI 1275776866
$1,952.17
in general payments reported to CMS, 2019-2025
20 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $125 · 2021: $113 · 2022: $159 · 2023: $460 · 2024: $362 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,350.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $322.80 | 2020-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $298.97 | 2025 | Watchman |
| Pfizer INC. | $281.23 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $197.80 | 2019-2025 | |
| Cvrx, INC. | $186.87 | 2023-2024 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $135.98 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.53 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $99.09 | 2021-2025 | Verquvo |
| Abbott Laboratories | $81.20 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $54.03 | 2023-2024 | Wainua, Farxiga, Andexxa |
| Ge Healthcare | $38.33 | 2025 | |
| Genmab U.S., INC. | $20.03 | 2025 | Epkinly |
| Lantheus Medical Imaging, INC. | $19.91 | 2019 | |
| Bracco Diagnostics INC. | $19.61 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.08 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $16.72 | 2023 | Erleada |
| W. L. Gore & Associates, INC. | $16.36 | 2022 | |
| Scpharmaceuticals INC. | $14.64 | 2025 | |
| Blueprint Medicines Corporation | $14.28 | 2025 | Ayvakit |
| Irhythm Technologies, INC. | $13.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.